3 Under-the-Radar Small-Caps Flying Below Every Radar Screen

IBD's Mike Webster had a great line this week: after running his weekend screen (stocks above the 21-day, 50-day, and 200-day, relative strength above 70), medical and biotech names kept showing up even after a rough week for the sector. That's the kind of stubborn resilience that usually precedes a re-rating. So we ran our own version of that screen, filtered for market caps under $10B, and came up with three names you've almost certainly never argued about on a group chat.

$NVCR (NovoCure, Nasdaq, ~$3.5B market cap) makes wearable electric field therapy devices for cancer, specifically a technology called Tumor Treating Fields. It's been approved for glioblastoma for years, but the company has been quietly grinding through clinical trials for lung cancer and other solid tumors. The catalyst here is real: a pivotal Phase 3 lung cancer readout could expand the addressable market by 5 to 6 times the current label. It's under the radar because wearable oncology devices don't get the GLP-1 or CAR-T hype cycle. The bear case is legitimate, too: the device is awkward to wear, payer coverage has been patchy, and the stock has been range-bound for over a year. But if that lung data hits, this thing doesn't stay at $3.5B for long.

$SKWD (Skyward Specialty Insurance, Nasdaq, ~$1.8B market cap) is a specialty commercial insurer focused on niche, hard-to-place risks: think excess and surplus lines, professional liability, and accident and health. Nobody talks about specialty insurers unless they blow up, which is exactly why this one is interesting. Bloomberg noted this week that reinsurance capital is abundant and reinsurance prices are falling after two consecutive mild hurricane seasons. That's actually margin-positive for a primary specialty insurer that buys reinsurance as a cost. The catalyst: Q3 earnings, expected in the next few weeks, where improving combined ratios could finally get some analyst attention. The bear case is that a surprise catastrophe event (like the hurricane making landfall in Florida this week) could spike reserves. But with VIX sitting at a calm 15.41 and volatility subdued, the near-term setup looks clean.

$TLYS (Tilly's, NYSE, ~$280M market cap) is the smallest and spiciest pick here. It's a specialty retailer selling youth action sports and lifestyle apparel, the kind of brand that Gen Z either loves or completely ignores depending on the week. The reason it's on the list: consumer spending data cited by PNC's Amanda Agati this week showed retail sales running above inflation despite weak sentiment surveys, with a potentially strong holiday setup ahead. Tilly's has a lean balance sheet and meaningful inventory discipline after two brutal years of post-pandemic normalization. The catalyst is holiday season performance, pure and simple. The bear case is obvious: it's a physical retailer in a world where TikTok shops and resale platforms are eating its lunch with the exact demographic it targets.

All three names share the same trait that makes them interesting right now: they're small enough that a single positive data point can move the stock materially, and they're obscure enough that the crowd hasn't priced in the upside. That's not a guarantee of anything, but in a market where the S&P 500 is near 7,811 and everyone is fighting over the same ten names, boring and overlooked is kind of the play.